The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases

Expert Opin Biol Ther. 2019 Oct;19(10):967-969. doi: 10.1080/14712598.2019.1566455. Epub 2019 Jan 11.
No abstract available

Keywords: Anti-TNF; biological therapy; biosimilar; inflammatory bowel disease; infliximab.

Publication types

  • Editorial

MeSH terms

  • Biosimilar Pharmaceuticals / chemistry
  • Biosimilar Pharmaceuticals / economics
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Health Personnel
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab / chemistry
  • Infliximab / therapeutic use
  • Patient Compliance

Substances

  • Biosimilar Pharmaceuticals
  • Infliximab